You are here

Home » Content

Matriks Metaloproteinazların Böbrek Hastalıklarındaki Rolü

The Role of Matrix Metalloproteinases in Renal Diseases

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2011
DOI: 
10.5262/tndt.2011.1002.01

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Matrix metalloproteinases (MMPs) are a family of zinc dependent proteinases and the main promoters of extracellular matrix degradation. Their role in renal diseases is now being understood better. Several progressive renal diseases are characterized with persistent cell proliferation and abnormal production of extracellular matrix by mesengial cells. Understanding mesengial cell proliferation and the factors regulating extracellular matrix metabolism is therefore becoming more important. MMPs have been shown to be produced and excreted from renal glomerular cells and interstitital fibroblast and tubuloepithelial cells have also been shown to excrete MMPs. MMPs function in expansive cell behaviour, embryonic evolution and tissue fibrosis. Production of MMPs are known to increase in inflammation and restructure processes. Data obtained from both experimental and clinical studies has shown the role of MMPs in proliferative glomerulonephritis, hypertensive nephropathy, diabetic nephropathy, HIV nephropathy, toxic nephropathy, obstructive nephropathy, renal cell carcinoma, chronic allograft nephropathy-related fibrosis and in many other renal diseases. In light of these data, therapy options targeting MMPs have become a current issue. Limited data obtained from recent studies are promising about the clinical use of therapies repressing MMPs in future. The roles of MMPs which increase in inflammation and restructure processes in renal diseases and future therapy options are discussed in this review.
Bookmark/Search this post with
Abstract (Original Language): 
Matriks metaloproteinazlar (MMP) çinko bağımlı, geniş bir aileye mensup enzimler olup, hücre dışı matriks yıkımının ana düzenleyicileridirler ve böbrek hastalıklarındaki rolleri giderek daha iyi anlaşılmaktadır. Birçok ilerleyici böbrek hastalığı, süregen hücre çoğalması ve mezengiyal hücreler tarafından hücre dışı matriksin anormal yapımı ile karakterizedir. Bu nedenle mezengiyal hücre çoğalması ve hücre dışı matriks metabolizmasını düzenleyen faktörlerin bilinmesi önem kazanmaktadır. Böbrek glomerüler hücrelerinde MMP’lerin üretilip salındığı, interstisiyel fibroblast ve tubüloepitelyal hücrelerin de MMP salgıladığı gösterilmiştir. MMP’ler böbrekteki yayılımcı hücre davranışı, embriyonik gelişim ve doku fibrozisi olaylarında görev alırlar. Yangı ve yeniden yapılanma işlemlerinde de MMP’lerin yapımlarının arttığı bilinmektedir. Gerek deneysel, gerekse klinik çalışmalardan elde edilen veriler sonucunda; proliferatif glomerülonefritler, hipertansif nefropati, diyabetik nefropati, HİV nefropatisi, toksik nefropati, obstrüktif nefropati, renal hücreli karsinom, kronik allograft nefropati ilişkili fibrozis ve daha birçok böbrek hastalığında MMP’lerin rolleri gösterilmiştir. Bu veriler eşliğinde, MMP’leri hedef alan tedavi seçenekleri gündeme gelmiştir. Yakın zamanlı çalışmalarda elde edilen sınırlı sayıdaki bulgular; MMP baskılayıcı tedavilerin gelecekte klinik uygulamalarda yer almaları konusunda umut verici görünmektedir. Bu derlemede yangı ve yeniden yapılanma işlemlerinde yapımları artan MMP’lerin, böbrek hastalıklarındaki rolleri ve gelecekteki tedavi seçenekleri tartışılacaktır.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_20_pp_109-114.pdf
  • 2
109-114
  • Turkish

REFERENCES

References: 

1. Kagami S, Border WA, Miller DE, Noble NA: Anjiotensin II
stimulates extracellular matrix protein synthesis through induction
of transforming growth factor-beta expression in rat glomerular
mesangial cells. J Clin Invest 1994; 93: 2431-2437
2. Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibitoin of
matrix metalloproteinases attenuates anti-Thy 1.1 nephritis. J Am
Soc Nephrol 1998; 9: 397-407
3. Lenz O, Elliot SJ, Stetler-Stevenson WG: Matrix metalloproteinases in
renal development and disease. J Am Soc Nephrol 2000; 11:574-581
4. Urushihara M, Kagami S, Kuhara T, Tamaki T, Kuroda Y: Glomerular
distribution and gelatinolytic activity of matrix metalloproteinases
in human glomerulonephritis. Nephrol Dial Transplant 2002; 17:
1189-1196
5. Uchio-Yamada K, Manabe N, Goto Y, Anann S, Yamamoto Y,
Takano K, Ogura A, Matsuda J: Decreased expression of matrix
metalloproteinases and tissue inhibitors of metalloproteinase in the
kidneys of hereditary nephrotic (ICGN) mice. J Vet Med Sci 2005;
67(1): 35-41
6. Martin J, Knowlden J, Davies M , Williams J: Identification and
independent regulation of human mesangial cell metalloproteinases.
Kidney Int 1994; 46: 877-885
7. Martin J, Steadman R, Knowlden J, Williams J, Davies M:
Differential regulation of matrix metalloproteinases and their
inhibitors in human glomerular epithelial cells in vitro. J Am Soc
Nephrol 1998; 9: 1629-1637
8. Sanders JS, Van Goor H, Hanemaaijer R, Kallenberg CG, Stegeman
CA: Renal expression of matrix metalloproteinases in human
ANCA-associated glomerulonephritis. Nephrol Dial Transplant
2004; 19: 1412-1419
9. Hayashi K, Horikoshi S, Osada S, Shofuda K, Shirato I, Tomino Y:
Macrophage-derived MT1-MMP and increased MMP-2 activity are
associated with glomerular damage in crescentic glomerulonephritis.
J Pathol 2000; 191: 299-305
10. Lelongt B, Bengatta S, Delauche M, Lund LR, Werb Z, Ronco PM:
Matrix metalloproteinase 9 protects mice from anti-glomerular
basement membrane nephritis through itd fibrinolytic activity. J Exp
Med 2001; 193: 793-802
11. Ahuja T, Gopalani A, Davies P, Ahuja H: Matrix metalloproteinase-9
expression in renal biopsies of patients with HIV-associated
nephropathy. Nephron Clin Pract 2003; 95: 100-104
Sağlam F: Matriks Metaloproteinazların Böbrek Hastalıklarındaki Rolü
114 Turk Neph Dial Transpl 2011; 20 (2): 109-114
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
12. Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH: Effects of
benazepril on renal function and kidney expression of matrix
metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in
diabetic rats. Chin Med J 2006; 119(10): 814-821
13. Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, Van Goor
H, Kreutz R: Expression and response to angiotensin-converting
enzyme inhibition of matrix metalloproteinases 2 and 9 in renal
glomerular damage in young transgenic rats with renin-dependant
hypertension. J Pharmacol Exp Ther 2006; 316(1): 8-16
14. Nazneen A, Razzaque MS, Liu D, Taguchi T: Possible role of
Ets-1 and MMP-1 in matrix remodelling in experimental cisplatin
nephropathy. Med Electron Microsc 2002; 35(4): 242-247
15. Iimura O, Takahashi H, Yashiro T, Madoiwa S, Sakata Y,
Asano Y, Kusano E: Effect of ureteral obstruction on matrix
metalloproteinase-2 in rat renal cortex. Clin Exp Nephrol 2004;
8(3): 223-239
16. Ikinen KA, Soots AP, Krogerus LA, Lautenschlager IT, Ahonen
JP: Fibrosis and matrix metalloproteinases in rat renal allografts.
Transpl Int 2005; 18(5): 506-512
17. Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heeman : Inhibition
of matrix metalloproteinases during chronic allograft nephropathy
in rats. Transplantation 2005; 79(6): 655-661
18. Kallakury B, Karikahalli S, Haholu A, Sheehan CE, Azumi N,
Ross JS: Increased expression of matrix metalloproteinases 1 and
2 correlate with poor prognostic variables in renal cell carcinoma.
Clin Canc Res 2001; 7: 3113-3119
19. Zeisberg M, Khurana M, Rao V, Cosgrove D, Rougier JP, Werner
MC, Shield CF, Werb Z, Kalluri R: Stage-specific action of matrix
metalloproteinases influences progressive hereditary kidney
disease. Plos Med 2006; 3: 535-545
20. Lods N, Ferrari P, Frey F, Kappeler A, Berthier C, Vogt B, Mart
HP: Angiotensin-Converting enzyme inhibition but not angiotensin
II receptor blockade regulates matrix metalloproteinase activity
in patients with glomerulonephritis. J Am Soc Nephrol 2003; 14:
2861-2872
21. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebhira I,
Koide H: Urinary excretion of podocytes in patients with diabetic
nephropathy. Nephrol Dial Transplant 2000; 15: 1379-1383
22. Kurogi Y: Mesangial cell proliferation inhibitors fort he treatment
of proliferative glomerular diease. Med Res Rev 2003; 23: 15-31
23. Ahuja TS: Doxycyline decreases proteinuria in glomerulonephritis.
Am J Kidney Dis 2003; 42(2): 376-380

Thank you for copying data from http://www.arastirmax.com